Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide  by Melgari, Dario et al.
Journal of Molecular and Cellular Cardiology 86 (2015) 42–53
Contents lists available at ScienceDirect
Journal of Molecular and Cellular Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate /y jmccOriginal articleMolecular basis of hERG potassium channel blockade by the class Ic
antiarrhythmic ﬂecainideDario Melgari a, Yihong Zhang a, Aziza El Harchi a, Christopher E. Dempsey b, Jules C. Hancox a,⁎
a School of Physiology & Pharmacology, Medical Sciences Building, University Walk, Bristol BS8 1TD, UK
b School of Biochemistry, Medical Sciences Building, University Walk, Bristol BS8 1TD, UK⁎ Corresponding author.
E-mail address: jules.hancox@bristol.ac.uk (J.C. Hanco
http://dx.doi.org/10.1016/j.yjmcc.2015.06.021
0022-2828/© 2015 The Authors. Published by Elsevier Ltda b s t r a c ta r t i c l e i n f oArticle history:
Received 21 April 2015
Received in revised form 19 June 2015
Accepted 30 June 2015
Available online 6 July 2015
Keywords:
Flecainide
hERG
QT interval
Repolarization
Torsades de PointesThe class Ic antiarrhythmic drug ﬂecainide inhibits KCNH2-encoded “hERG” potassium channels at clinically
relevant concentrations. The aim of this study was to elucidate the underlying molecular basis of this action.
Patch clamp recordings of hERG current (IhERG) were made from hERG expressing cells at 37 °C. Wild-type
(WT) IhERG was inhibited with an IC50 of 1.49 μM and this was not signiﬁcantly altered by reversing the direction
of K+ ﬂux or raising external [K+]. The use of charged and uncharged ﬂecainide analogues showed that the
charged form of the drug accesses the channel from the cell interior to produce block. Promotion of WT IhERG
inactivation slowed recovery from inhibition, whilst the N588K and S631A attenuated-inactivation mutants
exhibited IC50 values 4–5 fold that of WT IhERG. The use of pore-helix/selectivity ﬁlter (T623A, S624A V625A)
and S6 helix (G648A, Y652A, F656A) mutations showed b10-fold shifts in IC50 for all but V625A and F656A,
which respectively exhibited IC50s 27-fold and 142-fold their WT controls. Docking simulations using a
MthK-based homology model suggested an allosteric effect of V625A, since in low energy conformations
ﬂecainide lay too low in the pore to interact directly with that residue. On the other hand, the molecule
could readily form π–π stacking interactions with aromatic residues and particularly with F656. We conclude
thatﬂecainide accesses the hERG channel from the cell interior on channel gating, binding low in the inner cavity,
with the S6 F656 residue acting as a principal binding determinant.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Flecainide is a class Ic antiarrhythmic drug that is used primarily in
the treatment of supraventricular arrhythmias [1] although, in the
absence of structural heart disease, it is sometimes used in the treat-
ment of ventricular tachycardias that are resistant to other treatment.
Guidelines from the American College of Cardiology, American Heart
Association and European Society of Cardiology, recommend ﬂecainide
as a front-line treatment option for pharmacological cardioversion of
atrial ﬁbrillation (AF) and for the maintenance of sinus rhythm in AF
patients (e.g. [2–4]). A 2011 review of 25 years of ﬂecainide use sup-
ports the notion that, with appropriate patient selection, ﬂecainide is
safe and effective in AFmanagement [5]. The importance of appropriate
patient selection arises, to a signiﬁcant extent, from the results of the
CAST trial, which showed increased mortality with class Ic (ﬂecainide
and encainide) drug treatment of patients surviving myocardial infarc-
tion (MI) [6]. Recent evidence supports an additional clinical application
of ﬂecainide in the treatment of catecholaminergic polymorphic ven-
tricular tachycardia (CPVT), particularly in cases where arrhythmias
are not completely suppressed by β-blocker therapy (e.g. [7–10]).x).
. This is an open access article underFlecainide's class Ic action is attributable to the drug's open state
dependent Na channel block and its Na channel association/dissociation
kinetics [1,5,11]. The drug can prolong ventricular and atrial action
potentials (APs), but shortens Purkinje ﬁbre APs (reviewed in [5]). Ther-
apeutic serum levels of ﬂecainide lie between ~0.5 and 2.4 μM [12].
Flecainide inhibits L-type calcium current at concentrations that consid-
erably exceed this range (IC50 of ~20 μM; [13]). Flecainide may also act
as an open-channel blocker and gating modiﬁer of the RyR2 ryanodine
receptor [7,14]. It is also an effective inhibitor of cardiac K+ channels
[15]. For example, ﬂecainide discriminates between Kv4.x and 1.4 chan-
nels that contribute to transient outward K+ current (being more
effective against the former subtype; [16]). It has also been shown to
inhibit the rapid delayed rectiﬁer K+ current, IKr [17–19] and recombi-
nant channels encoded by human Ether-à-go-go-Related Gene (hERG;
[20–24]). The agent's IKr/hERG blockade occurs at concentrations that
overlap the clinical concentration range [20,21,24] and, as noted by
Aliot and colleagues, the drug's inhibitory effects on INa and IKr occur
at lower concentrations than those on other channels [5]. They are
therefore the ion channel effects that are likely to predominate during
clinical use of the drug. Although rarely associated with Torsades de
Pointes (TdP) arrhythmia or QT interval prolongation, some cases have
been reported in which rate-corrected QT interval prolongation was
not fully accounted for by widening of the QRS complex, and/or thatthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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a role for IKr inhibition (e.g. [25–28]).
Flecainide has been reported to exhibit characteristics of a compara-
tively rapidly acting, gated state dependent hERG channel blocker [20]
and, in marked contrast to high afﬁnity methanesulphonanilide inhibi-
tors of hERG current (IhERG) [29,30], ﬂecainide block of IhERG develops
rapidly on membrane depolarization [20]. Other class I antiarrhythmics
that have been investigated in detail have shown a restricted set of
binding residues and a relatively modest dependence of hERG channel
blockade on inactivation gating [31–34]. In contrast, data on the under-
lying basis of ﬂecainide inhibition of IhERG are at present lacking.
The present study was conducted to address this deﬁcit, through inves-
tigation of the role of IhERG inactivation and the roles of major pore
helical and S6 helical residues in ﬂecainide's inhibitory action.
2. Methods
2.1. Wild-type and mutant hERG channels
The mammalian cell line (Human Embryonic Kidney HEK293) stably
expressing wild-type (WT) hERG channels was kindly donated by
Prof Craig January [30]. The pore helix (T623A, S624A and V625A) and
S6 helix (G648A and F656A) alanine mutants and the attenuated-
inactivation mutants S631A, N588K and N588K/S631A were generated
and used as described previously [33–36]. The HEK293 cell line stably ex-
pressing the hERG S6 helix mutant Y652A was used as described
previously [35].
2.2. Maintenance of mammalian cells lines and cell transfection
HEK cells stably or transiently expressing hERG channel constructs
were cultured as previously described [34,37]. The cells were plated
in 40 mm petri dishes at least 48 h before transfection and incubated
at 37 °C (5% CO2). Cells were transfected with Lipofectamine™ LTX
(Invitrogen) following the manufacturer's instructions. The amount of
transfected hERG construct DNA varied between 0.2 and 1.0 μg
depending on the level of functional expression (assessed as current
magnitudes) of each hERG channel construct. 0.5 to 1.0 μg of CD8 was
co-transfected as a transfection-marker and successfully transfected
cells were identiﬁed using Dynabeads® (Invitrogen). Cells were plated
on small sterilized glass shards in 40 mm petri dishes and incubated
at 37 °C (5% CO2) for at least 24 h before electrophysiological recording.
2.3. Electrophysiology
Glass shards containing plated cells were placed in a recording
chamber mounted on an inverted microscope (Nikon Diaphot, USA).
The cells were continuously superfused with a pre-warmed (37 °C)
standard Tyrode's solution containing (in mM) the following: 140
NaCl, 4 KCl, 2.5 CaCl2, 1 MgCl2, 10 Glucose, 5 HEPES (titrated to pH 7.4
with NaOH). A modiﬁed “High K+” version of this solution (containing
94 mM KCl and 50 mM NaCl) was used to elicit recordable currents
from T623A, G648A and F656A hERG channels mutants [34,37]. Glass
patch-pipettes (Schott #8250 glass, A-M Systems Inc., USA)were pulled
(Narishige, PP 830) and polished (Narishige, MF 83) to obtain a ﬁnal
resistance between 2 and 4 MΩ. Patch-pipettes were dialysed with an
intracellular solution containing (in mM) the following: 130 KCl, 1
MgCl2, 5 EGTA, 5 MgATP, 10 HEPES (titrated to pH 7.2 with KOH). All
recordings were made using an Axopatch 200B ampliﬁer (Axon Instru-
ments, now Molecular Devices) and a CV203BU head-stage. Pipette
resistance compensation was between 70 and 80%. Data were acquired
using a Digidata 1320 interface (Axon Instruments, now Molecular
Devices). Data digitization rates were 10–25 kHz during all voltage
protocols and an appropriate bandwidth of 2–10 kHz was set on the
ampliﬁer.2.4. Data analysis and statistics
Data analysiswasperformedusingClampﬁt 10.3 (Axon Instruments,
now Molecular Devices), Prism v4.03 and 5.03 and Excel 2013. Data
are presented as the mean ± SEM or as mean with ±95% Conﬁdence
Interval (CI). Equations used to ﬁt particular data-sets are given in the
online supplement. For statistical analysis, data were subject to the
Kolmogorov–Smirnov normality test. Statistical comparisons were
made using paired or unpaired two-tailed t tests, Wilcoxon matched
pairs signed rank test, Mann–Whitney U test and one way (repeated
measures, where indicated) or two way ANOVA, as appropriate. Details
of the statistical test used to evaluate signiﬁcance for results of particu-
lar experiments are given alongside “p” values in the Results text or in
the relevant table or ﬁgure legend. p values less than 0.05 were taken
as statistically signiﬁcant.
2.5. Molecular modelling and docking
A homology model of the open conﬁguration of the hERG channel
pore region (pore helix, selectivity ﬁlter and S6 helices) based on the
crystal structure of MthK channel [38] was used to perform docking
simulations with ﬂecainide using GOLD. Further details are provided
in the online supplement.
3. Results
3.1. Effect of ﬂecainide on WT hERG in different experimental conditions
Concentration-dependent block of WT IhERG by ﬂecainide was
studied by the repeated application (start-to-start interval of 12 s) of
the voltage protocol shown in the lower panel of Fig. 1A (see also [24,
34,37]). Block of IhERG was assessed by calculating the reduction in
drug of the outward ‘tail’ current at−40mV (assessed as the difference
in magnitude between peak tail current and instantaneous current
activated by the brief (50 ms) depolarization from −80 to −40 mV
[24,34,37]). Flecainide acted rapidly [20], and steady-state inhibition
was attained within 3 min of drug application. Fig. 1A shows repre-
sentative records of WT IhERG in the absence (control) and in the
presence of ﬂecainide (1 μM). The fractional inhibition at each of
four concentrations was calculated using Eq. (1) (supplementary infor-
mation) and themean values were plotted as shown in Fig. 1D and then
ﬁtted with a standard Hill equation (Eq. (2), supplementary informa-
tion). This yielded a half-maximal inhibitory concentration (IC50) of
1.49 μM (CI: 1.27–1.74) with a Hill coefﬁcient (nH) of 0.81 (CI: 0.68–
0.93), in accord with previously observed values under similar experi-
mental conditions [20,24]. Consistent with previous data [20], the in-
hibitory effect of ﬂecainide on IhERG exhibited voltage dependence
(Fig. S1), with a concomitant leftward shift (~–7 mV) in voltage depen-
dent activation. The low expression and kinetics of some mutant chan-
nels included in this study requires that IhERG be studied as an inward
current in high (94 mM) [K+]o [34,35,37]. Consequently, ﬂecainide
block of WT IhERG was also studied under comparable experimental
conditions. Fig. 1B and C show the effect of 1 μM ﬂecainide on inward
WT IhERG elicited at −120 mV in normal Tyrode's and in High [K+]o
Tyrode's respectively; concentration response relations under these
conditions are plotted in Fig. 1D. The ﬁts to the experimental data
gave an IC50 of 1.05 μM (CI: 0.82–1.38) with a nH of 0.67 (CI: 0.57–
0.77) for inward WT IhERG in normal Tyrode's solution and an IC50 of
1.25 μM (CI: 0.97–1.60) with a nH of 0.56 (CI: 0.48–0.67) for inward
WT IhERG in High [K+]o.. Thus ﬂecainide inhibition of IhERG was not
sensitive to the direction/magnitude of K+ ﬂux. Under action potential
(AP) voltage clamp [37], peak IhERG during AP repolarization (Fig. 1E)
was inhibited by 38.3 ± 1.7% (n = 6), which is not signiﬁcantly differ-
ent from the fractional inhibition of the tail current (with the standard
protocol) induced by the same drug concentration (41.7 ± 2.2% (n =
21); Fig. 1F, p N 0.05 unpaired t-test).
Fig. 1. Effect of ﬂecainide on WT IhERG. (A) Upper traces show WT IhERG elicited by a standard protocol (lower trace) before (black) and during (grey) exposure to 1 μM ﬂecainide.
(B) InwardWT IhERG (upper traces) measured at−120mV following an activating command to+20mV, before (black) and during (grey) exposure to 1 μM ﬂecainide. The current traces
are displayed to focus on the portion corresponding to repolarization from+20 to−120mV. (C) InwardWT IhERGmeasured at−120mV following an activating command to+20mV in
high [K+]o (94 mM) before (black) and during (grey) exposure to 1 μM ﬂecainide. (D) Concentration–response relations for ﬂecainide inhibition of WT IhERG elicited under the different
experimental conditions in A, B and C (n ≥ 5 at each concentration). IC50 and nH values are given in the Results text. (E) Upper traces showWT IhERG elicited by an AP voltage command
before (black) and during (grey) exposure to 1 μM ﬂecainide. (F) Comparison between the effect of 1 μM ﬂecainide onWT IhERG elicited by the standard protocol shown in ‘A’ (n=21) and
the AP voltage command (n = 6) (ns, p N 0.05 unpaired t-test vs. Standard).
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Membrane “sidedness” of ﬂecainide action was explored using
two ﬂecainide analogues used in prior investigation of the drug's
block of sodium channels (Fig. 2A— a fully charged ﬂecainide analogue
QX-Flec and the ~90% neutral analogue NU-Flec (pKa 6.3) [39]). We
tested the effect of two concentrations (10 and 100 μM) of each
analogue applied from the cell exterior (superfusate) and interior (thelatter through the patch-pipette). Fig. 2Bi summarizes the results from
the external application of the analogues compared to the parent
compound. Sample traces of IhERG elicited by a standard voltage protocol
in control and in the presence of 100 μM of QX-Flec and Nu-Flec
are shown in Fig. 2Bii and Biii respectively. Each analogue was
superfused over the cell under study for 6–8 min and both exhibited
a reduction in potency compared to ﬂecainide. For 10 and 100 μM QX-
Flec, the fraction of unblocked IhERG was 72.2 ± 4.6% (n = 9) and
Fig. 2.Effect of ﬂecainide analogues onWT IhERG. (A) Chemical structure of ﬂecainide (left, pKa 9.3), QX-Flec (centre) and NU-Flec (right, pKa 6.3) drawnwith ChemBioDrawUltra
14.0 (CambridgeSoft). (Bi) External application of two concentrations (10 μM, black and 100 μM, white) of ﬂecainide (n = 10 and 6 respectively), QX-Flec (n = 9 and 10 respec-
tively) and NU-Flec (n = 8 and 10 respectively); data are shown as Unblocked Current remaining after drug exposure (plotted as IDrug/IControl) (***p b 0.001 one-way ANOVA
with Bonferroni post hoc). (Bii, Biii) Sample traces of WT IhERG before (black) and during (grey) the external application of (Bii) QX-Flec 100 μM and (Biii) NU-Flec 100 μM.
(Ci) Current density for IhERG (pA/pF) with internal application (via the patch pipette) of two concentrations (10 μM, black and 100 μM, white) of QX-Flec (n = 7 and 5 respec-
tively) and NU-Flec (n = 6 and 12 respectively) compared with IhERG density with normal (drug-free) pipette solution (grey, n = 10. i.e. normal pipette solution; *p b 0.05,
**p b 0.01 and ns p N 0.05, one-way ANOVA with Bonferroni post hoc vs. control). (Cii, Ciii) Sample traces of WT IhERG (grey) recorded at 6 min of internal exposure (from gaining
whole cell access) to (Cii) QX-Flec 100 μM and (Ciii) NU-Flec 100 μM.
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an unblocked current fraction of 75.8 ± 4.4% (n = 8) and 50.2 ± 4.3%
(n = 10) respectively (p b 0.001, one-way ANOVA with Bonferroni
post hoc test). Pipette application of two different concentrations of
QX-Flec and NU-Flec from the patch-pipette was determined. As soon
as the whole-cell conﬁguration was achieved the drug molecules werefree to diffuse inside the cytoplasm, precluding cells acting as their
own control. Instead, time matched (~6 min) measurements of IhERG
density (with 10 or 100 μMQX-Flec orNU-Flec; Fig. 2Ci)were compared
with measurements from cells dialysed with drug-free standard
intracellular solution. Fig. 2Cii and Ciii show IhERG traces after 6 min of
internal perfusion with 100 μM QX-Flec and NU-Flec respectively.
46 D. Melgari et al. / Journal of Molecular and Cellular Cardiology 86 (2015) 42–53Mean values are reported in Fig. 2Ci. When dialyzed with 10 or 100 μM
QX-Flec the whole-cell current density was 55.3 ± 5.9 pA/pF (n = 7)
and 9.3 ± 1.9 pA/pF (n = 5) respectively, and both values are signiﬁ-
cantly different from control (315.3 ± 56.7 pA/pF (n = 10), p b 0.05
and p b 0.01 respectively, one-way ANOVA with Bonferroni post hoc).
Conversely, there was no signiﬁcant difference in IhERG density between
control cells and cells dialyzed with 10 or 100 μM NU-Flec (283.2 ±
63.4 pA/pF (n = 6) and 359.8 ± 56.1 pA/pF (n = 12) respectively,
p N 0.05 one-way ANOVA with Bonferroni post hoc). The results of
these experiments are consistent with prior data for SCN5A sodium
channels, for which both analogues were less effective when applied
from the cell exterior, whilst QX-Flec was particularly effective when
applied directly to the cell interior [39].
3.3. Relationship between ﬂecainide block and hERG channel inactivation
IhERG inhibition by a number of cardiac and non-cardiac drugs is
inﬂuenced signiﬁcantly by channel inactivation (e.g. [31,33,40,41]),
although class I antiarrhythmic drugs examined to date appear not to
depend strongly on inactivation to block the channel [31,33,34].
Fig. 3A and B show the effect of ﬂecainide on IhERG availability, studied
with the three-step protocol reported in the inset of Fig. 3Ai [36,42].
The resurgent transient current elicited at the beginning of the third
step at +40 mV was analysed as previously described [36,42]. Fig. 3Ai
and Aii show sample traces of resurgent IhERG in control and in the pres-
ence of 1 μM ﬂecainide respectively (for clarity currents at selected volt-
ages are shown). Mean values of normalized current were plotted
against the corresponding test voltage during the 2 ms step (Fig. 3B)
andﬁttedwith a Boltzmann function (Eq. (3), supplement). This yielded
a V0.5 of inactivation of−53.4±2.3mVwith a Slope factor of 20.9±0.5
(n=6) in the control and a V0.5 of inactivation of−54.6± 2.9mVwith
a Slope of 22.1± 0.9 (n=6) in the presence of 1 μM ﬂecainide (p N 0.05
for both parameters versus control; Wilcoxon matched-pairs signed
rank test). Thus, ﬂecainide did not signiﬁcantly alter the voltage depen-
dence of hERG channel inactivation. The effect of ﬂecainide on the time-
course of IhERG inactivation was assessed by ﬁtting the decay of the
resurgent current elicited at the beginning of the third step after a
hyperpolarizing step to −120 mV with a monoexponential function
(Eq. (4), supplement). The results are summarized in Fig. 3C. Flecainide
slightly but signiﬁcantly increased the time constant of inactivation at
−120mV from1.15±0.09ms to 1.47±0.09ms (n=6, p b 0.01 paired
t-test). In further experiments, the extent to which C-type inactivation
might stabilize the binding of ﬂecainide to hERG channels was investi-
gated by washing the drug off during sustained depolarization. To do
so we applied a long (15 s) depolarizing step to 0 or +40 mV in
control and in the presence of 1 μM ﬂecainide (Fig. 3D). When the
steady-state of block was reached the perfusion system was quickly
switched back to control during the depolarizing pulse. The half-time
of recovery (thalf recovery) was calculated. At 0 mV the thalf recovery
was 1.42 ± 0.20 s (n = 5) and at +40 mV it was 2.19 ± 0.24 s (n =
5) (Fig. 3E; p b 0.05, unpaired t-test). The slower recovery ofmacroscop-
ic IhERG at the more depolarized potential is suggestive that the drug is
more tightly bound to hERG channels in the inactivated state.
The inactivation-dependence of ﬂecainide block of hERG was
studied further using mutants with impaired inactivation (Fig. 4).
Different ﬂecainide concentrations were tested on the S631A and
N588K hERG mutations which share a similar rightward shift in the
voltage dependence of inactivation [33], but which are located in differ-
ent regions of the channel (the pore and S5-pore linker respectively).
Effects were also studied of the N588K/S631A double mutant which is
known to have a more severe impairment of channel inactivation than
either single mutant [33]. Fig. 4A–C shows expanded current traces of
these three mutants elicited by a standard protocol in control and in
the presence of 10 μM ﬂecainide. Experimental data were plotted and
analysed for WT channels, with concentration–response relations
shown in Fig. 4D. S631A and N588K showed similar sensitivities toﬂecainide, with an IC50 of 7.49 μM (CI: 6.33–8.87) and 6.50 μM (CI:
5.37–7.88) and nH of 0.77 (CI: 0.68–0.85) and 0.72 (CI: 0.63–0.81) for
S631A and N588K, respectively. This corresponds to a ~5-fold increase
in the IC50 value for S631A and a ~4.4-fold increase for N588K compared
withWT. TheN588K/S631Adoublemutant showed a further shift in the
dose–response relationshipwith an IC50 of 19.2 μM(CI: 15.3–23.8) with
a nH of 0.72 (CI: 0.62–0.82)which corresponds to a ~ 13-fold decrease in
potency compared to WT.
3.4. Effect of mutations in the hERG pore helix on ﬂecainide potency
A cluster of three residues (T623, S624 and V625) located in the
lower portion of pore helix-selectivity ﬁlter region has been reported
to be involved in the binding to hERG of different drugs (e.g. [43–45]).
In order to determine the roles of these residues in ﬂecainide block of
IhERG we studied alanine mutants of each of T623, S624 and V625. The
T623A mutant was tested in High [K+]o and the current was elicited
by a hyperpolarizing step to−120mV in order to obtain an appreciable
inward current transient. The S624A mutant was studied in normal
Tyrode's solution and the current was elicited by a standard voltage
protocol. The V625Amutantwas also tested in normal Tyrode's solution
but the current was elicited by the same hyperpolarizing protocol used
for T623A [34,37]. Sample traces of T623A, S624A and V625A currents in
control and in the presence of 10 μM ﬂecainide are shown in Fig. 5A, B
and C respectively. Different ﬂecainide concentrations were tested and
a full concentration–response relationship was constructed for each
mutant. The derived IC50s are reported in Fig. 5G and Table 1 together
with the values from WT hERG under matching experimental condi-
tions (see Fig. 1A–D). The calculated IC50 for T623A was ~5.6-fold that
for its WT control. For S624A the IC50 was ~1.8-fold its WT control.
The IC50 for V625A was ~27-fold its WT control.
3.5. Effect of S6 helix mutations on ﬂecainide potency
To investigate potential binding determinants in the pore region
we studied alanine mutants of three residues (G648, Y652 and F656)
located within the channel inner cavity on the S6 helix. G648 is a
highly conserved residue involved in the binding of high afﬁnity
methanesulphonanilide agents [43,44], whilst the aromatic Y652 and
F656 residues are of fundamental interest as interactions with at least
one of the two have been found to be important for the majority of
drugs tested [43–46]. G648A and F656A were studied under the same
experimental condition as T623A, whilst Y652A was tested in normal
Tyrode and the current was elicited by a standard voltage protocol.
Sample traces for G648A, Y652A and F656A IhERG in control and in the
presence of 10 μM ﬂecainide are shown in Fig. 5D, E and F, respectively.
Different concentrations were tested and the IC50 values from the
resulting concentration response relationships are plotted in Fig. 5G
for comparison with their respective WT controls, with mean IC50 and
nH values given in Table 1. The derived IC50 for G648A was ~9-fold its
WT control, that for Y652A was 3.4-fold its WT control and that for
F656A was 142-fold its WT control, with an nH of 0.55 (CI: 0.47–0.63).
These results support a particularly strong role for the F656 residue in
ﬂecainide binding. This was conﬁrmed in further experiments using pi-
pette application of the charged analogue QX-Flec, which produced lit-
tle inhibition of F656A hERG (see Fig. S2).
3.6. Docking simulation of ﬂecainide with a WT hERG model
Recent studies have proposed different models of ﬂecainide binding
to Kv2.1 and Kv1.5 channels [47,48]. In those models ﬂecainide was
proposed to interact with potassium sites in the central cavity and
with residues located at the subunit interface between S6 and P-
helices. Here we tested ﬂecainide on a MthK-based hERG channel
model [38] using the docking program GOLD. Several different low en-
ergy conformations were obtained that broadly conformed with
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molecule tended to adopt an extended conformation, and in most of
the low energy poses ﬂecainide docked low in the pore cavity lying
between the two aromatic residues F656 and Y652. In this position
the piperidine ring and the benzamide moiety of ﬂecainide formed
stacking π–π interaction with the surrounding cluster of aromatic
rings, in particularwith F656 (Fig. 6B). This is consistentwith the exper-
imental data in showing a strong dependence of ﬂecainide binding on
the presence of the F656 aromatic side chain. This simulation also
suggests an allosteric role of V625 residue in the selectivity ﬁlter region,
since the drugmolecule lies too far away to develop a direct interaction
with V625. Similar results were obtained in a second series of docking
runs using the program Flexidockwhich better accounts for electrostat-
ic contributions to binding [38] (see Supplement). For other drugmole-
cules Flexidock tends to locate the positively charged portion of the
drug closer to the selectivity ﬁlter and in or near the binding site for
K+ ions. However, in our analyses with ﬂecainide most of the low ener-
gy conformations had ﬂecainide docked to the inner mouth of the pore
interacting mainly with F656 aromatic rings (see Fig. S3).
4. Discussion
Flecainide was originally shown to inhibit feline ventricular E-4031
sensitive delayed rectiﬁer current with an IC50 of 2.1 μM [17,18]. At
high concentrations (10 and 30 μM) it was found to inhibit guinea-pig
ventricular IKr with selectivity over the slow delayed rectiﬁer current,
IKs [19]. Subsequently reported IC50 values for ﬂecainide inhibition of
WT IhERG from mammalian expression systems range from 0.74 to
3.91 μM [20,21,24]. The observed potency of ﬂecainide against WT
IhERG in the present study falls within this range and is consistent with
the potential for direct IKr/IhERG inhibition at clinical concentrations
[12]. In addition to exerting an acute inhibitory effect on IhERG, some
drugs are also able to impair hERG trafﬁcking [49–51]. Indeed, in one
study, 40% (20 of 50) of drugs producing a direct inhibitory effect on
IhERG also produced trafﬁcking defects [50]. The focus of the present
study was to establish molecular determinants of the acute IhERG inhib-
itory effects of ﬂecainide; the drug's effects on hERG channel trafﬁcking
were not investigated and remain to be established.
4.1. Gating dependence of ﬂecainide block and intracellular access to the
drug binding site
Flecainide has been reported to exhibit both (rapid) time and
voltage-dependent inhibition of IhERG [20] and the present study
(Fig. S1) afﬁrms voltage-dependence of the drug's action. The role of in-
activation gating in the drug's action has not hitherto systematically
been investigated. The lack of leftward shifted WT IhERG inactivation
seen here with ﬂecainide suggests that the drug does not act strongly
to stabilize the inactivated state, although the time-course of inactiva-
tion was modestly slowed by the drug (Fig. 3). On the other hand,
the slower washout of ﬂecainide during sustained depolarization to
+40 mV compared to 0 mV, which promoted IhERG inactivation
(Fig. 3D, E), suggests that inactivation plays a role in stabilizing the
drug within the channel. Our experiments with the S631A and N588K
single and double mutations (Fig. 4), yielded an increased IC50 for inhi-
bition of channels with impaired inactivation, which further supports
this notion. The ~4–5 fold shift in IC50 with the N588K and S631Amuta-
tions and ~13-fold shift for the double mutant compare with an IC50 for
IhERG inhibition by the methanesulphonanilide E-4031 that was in-
creased 11–12 fold by the two single mutants and ~36-fold by the
N588K/S631A double mutant [33]. Table S1 shows further comparisons
of the effects of inactivation mutations on the action of ﬂecainide with
comparable values for other class I and III agents. Considered in this
context, ﬂecainide inhibition of IhERG shows greater dependence on
inactivation than other class I agents studied to date, but less depen-
dence than that observed for methanesulphonanilides.In a prior study from our laboratory, intracellular dialysis via the
patch pipette of ﬂecainide produced less inhibition of IhERG than did
extracellular application of the same drug concentration [24]. Addition-
ally, extracellular ﬂecainide block of IhERG was also not sensitive to
acidiﬁcation of the pipette solution (although it was to extracellular
acidosis). These observations led to a suggestion that ﬂecainide may
not access its binding site on the hERG channel from the cell interior
[24]. These prior observations are consistent with results on ﬂecainide
block of native cardiac INa and SCN5A-encoded recombinant sodium
channels, as— despite acting as an open channel blocker— intracellular
ﬂecainide (again applied via the patch pipette) had been reported to
be relatively ineffective at inhibiting INa [39,52]. In experiments using
QX-Flec and NU-Flec, Liu and colleagues were able to resolve the mem-
brane ‘sidedness’ of ﬂecainide block and the role of drug ionization in Na
channel block [39]. They found that permanently charged ﬂecainide
was effective only when applied to the cell interior [39]. Flecainide has
a pKa value of 9.3, meaning that the majority, but not all of the parent
drug would be expected to be ionized at normal extracellular and intra-
cellular pH values. Liu et al proposed that the apparent ineffectiveness of
parent ﬂecainide when applied internally could be explained by a
scheme in which the small neutral component of drug leaves the cell
by crossing the cell membrane and is then rapidly diluted and washed
away by external superfusate, with intracellular re-equilibration/
partition between charged and uncharged drug then followed by fur-
ther uncharged drug egress, leading to dramatic attenuation of action
of the pipette-applied ﬂecainide (see [39]). This interpretation may
also explain prior observations in respect of pipette applied ﬂecainide
on IhERG [24]. In our experiments with QX-Flec and NU-Flex on hERG,
the former but not latter compoundwas an effective inhibitor when ap-
plied via the patch pipette. The modest component of IhERG inhibition
seen when QX-Flec was externally applied is consistent with some pas-
sage across the membrane of the quaternary analogue (cf [53]). Thus,
the data in the present study are consistent with a scheme in which ex-
ternally applied ﬂecainide crosses the cell membrane and once inside
the cell interior the charged fraction of drug enters the channel on acti-
vation gating to exert its inhibitory effect. Independent support for the
idea that ﬂecainide acts to inhibit hERG from the cell interior comes
from the observation that the drug's action is potentiated in cells
transfected with the drug uptake transporter OCTN1 [22].
4.2. Binding determinants within the hERG inner cavity
High afﬁnity pharmacological inhibition of hERG channels is charac-
terized by drug interactions with a binding site in the inner cavity in-
volving multiple actions with pore-helical and S6 residues (e.g. [43,44,
53–55]). For the methanesulphonanilide agent MK499, the Y652A mu-
tation increased the IhERG IC50 94-fold, whilst F656A increased it 650
fold. G648A resulted in an IC50 55-fold that of WT IhERG whilst for
T623A, and V625A the corresponding increases were 5 fold and 50
fold, respectively [43]. The related agents E-4031 and dofetilide have
similar binding determinants [44]. In contrast, high afﬁnity block by
both cisapride and terfenadine has been reported to involve both S6 ar-
omatic residues and T623 and S624 pore-helical residues, but not V625,
G648 and V659 residues, indicating that different molecules producing
high afﬁnity block can adopt distinct binding modes within the
channel's inner cavity [43,54]. By comparison with these drugs,
ﬂecainide has a more restricted set of binding determinants. In the
case of the cardiac Na channel ﬂecainide shares consensus tyrosine
(Y) and phenylalanine (F) binding residues (F1760 and Y1767) on the
SCN5A-encoded protein to those of lignocaine [39], whilst for Kv1.5mu-
tating one of the identiﬁed binding determinants, V505, to phenylala-
nine increased blocking potency 9-fold [56]. For ﬂecainide, our data
indicate that F656 but not Y652 acts as a key determinant of IhERG inhi-
bition, the crucial role for F656 being further demonstrated by the loss
of a signiﬁcant inhibitory effect of QX-Flec with the F656A mutation.
For the class Ia antiarrhythmic quinidine the F656Vmutation increased
48 D. Melgari et al. / Journal of Molecular and Cellular Cardiology 86 (2015) 42–53the IhERG IC50 by ~27 fold [31], whilst F656A and Y652A mutations in-
creased IhERG IC50 for disopyramide respectively by ~55 and ~51 fold re-
spectively [34], and so ﬂecainide appears to be more sensitive tomutation of F656 than is either of these drugs. In prior experiments
using Xenopus oocyte expression, the inhibitory action of the class Ia an-
tiarrhythmic drug ajmaline on IhERG was greatly impaired by both the
Fig. 4. Flecainide block of IhERG carried by attenuated-inactivation mutants. (A) Upper traces show S631A IhERG elicited by a standard protocol (expanded portion shown as lower trace;
protocol identical to that used to studyWT IhERG in Fig. 1A) in control (black) and in the presence of 10 μM ﬂecainide (grey). (B) Upper traces show N588K IhERG elicited by same protocol
as ‘A’ in control (black) and in the presence of 10 μM ﬂecainide (grey). (C) Upper traces show N588K/S631A IhERG elicited same protocol as ‘A’ in control (black) and in the presence of
10 μM ﬂecainide (grey). (D) Concentration response relations for the effect of ﬂecainide on the three attenuated-inactivation hERG mutants: S631A (grey circles and grey dashed line),
N588K (black circles, black dashed line) and N588K/S631A (white square, solid black line) compared with WT relation, replotted from Fig. 1D (white circles, dotted black line) (n ≥ 5
for each concentration of each curve).
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WT IhERG; 300 μM) was found to be ineffective against both mutants,
from which it is possible to conclude that the Y652 residue plays a
more prominent role in the binding of ajmaline than of ﬂecainide [57].
However, as full concentration–response data are not available for
ajmaline and these mutants [57], quantitative comparison between
ajmaline and ﬂecainide of the relative importance of residue F656 for
binding is not possible. To our knowledge, the only other class Ic drug
for which hERG binding determinants have been investigated is
propafenone [32]. Although structurally distinct from ﬂecainide,Fig. 3.WT IhERG inactivation and ﬂecainide. (A) Upper traces showWT IhERG elicited by the “ava
+40mV (500ms) and then brieﬂy (2ms) repolarized to a test potential ranging from−140mV
on the boxed area from the full protocol) in control (Ai) and in the presence of 1 μM ﬂecainide (
the application of 1 μM ﬂecainide (grey circles) (n = 6, ns p N 0.05 Wilcoxon matched-pairs si
tivation ofWT IhERG at+40mV after a hyperpolarizing step to−120mV in control and in the pr
IhERG elicited by a long (15 s) depolarizing step to 0 mV (Di) and +40 mV (Dii) in control (bla
superfusate was switched from drug to control, in order to wash out ﬂecainide. (E) Half-time
0 mV and +40 mV (*p b 0.05, unpaired t-test. n = 5 for both).propafenone shares with ﬂecainide a relative lack of dependence of
hERG block on interactions with Y652 (IC50 6.3-fold that of WT IhERG)
and a marked dependence on F656 (IC50 ~ 95-fold and ~56-fold the
values for WT IhERG in low and high [K+]o respectively) [32].
Propafenone showed relatively little sensitivity to T623A, S624A and
V625A mutations [32], whilst disopyramide has also been shown to be
little affected by T623A and S624A, with only a small effect of V625A
[34]. Although the effect of the V625A mutation on ﬂecainide's IhERG in-
hibitory action in vitro was marked, the in silico docking in the present
study supports an indirect role for this residue as in low energy bindingilability protocol” (from a holding potential of−80 mV themembrane was depolarized to
to+50mVbefore returning to+40mV. Full protocol shown in the inset; the traces focus
Aii). (B) Voltage dependence of inactivation forWT IhERG in control (black circles) and after
gned rank test). V0.5 and k values are given in the Results text. (C) Time constants of inac-
esence of 1 μM ﬂecainide (**p b 0.01, paired t-test, n=6). (D) Representative traces ofWT
ck) and in the presence of 1 μM ﬂecainide (grey). Black arrows indicate the time at which
recovery of the current recovery from ﬂecainide block during a long depolarizing pulse at
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Table 1
Effect of pore helix and S6 mutations on IhERG inhibition by ﬂecainide.
The table shows the effects of mutations in the pore-helix/selectivity ﬁlter region (T623A, S624A, V625A) and S6 helix (G648, Y652A, F656A) on IhERG block by ﬂecainide. WT-1,
WT-2,WT-3 refer to the 3 conditions under whichWT IhERG IC50 values were obtained. For all channel variants, the voltage-step shows the membrane potential at which IhERG tails were
measured and the corresponding external potassium ([K+]o) values are given. For each channel/recording condition the mean IC50 and nH values are given and for eachmutant, the fold
change in IC50 relative to its corresponding WT control is also given (IC50 mutant/IC50 of WT-control).
Channel Voltage step
mV
K+
mM
IC50 mean (±95% CI)
μM
n(H) mean (±95% CI) Shift in potency compared
to its WT-control
WT-1 −40 4 1.49 (1.27–1.74) 0.81 (0.68–0.93)
WT-2 −120 4 1.05 (0.82–1.38) 0.67 (0.57–0.77)
WT-3 −120 94 1.25 (0.97–1.6) 0.56 (0.48–0.67)
T623A −120 94 6.97 (5.80–8.38) 0.60 (0.54–0.67) 5.58
S624A −40 4 2.64 (2.30–3.03) 1.12 (0.94–1.30) 1.77
V625A −120 4 28.9 (23.4–35.6) 0.71 (0.62–0.80) 27.52
G648A −120 94 11.1 (9.56–12.8) 0.67 (0.61–0.73) 8.88
Y652A −40 4 5.09 (4.00–6.46) 0.60 (0.53–0.68) 3.42
F656A −120 94 176.9 (143.9–217.3) 0.55 (0.47–0.63) 141.52
Ai
Aii
B
3.7Å 3.3Å
Fig. 6. In silico docking simulations of ﬂecainide to hERG. (A) Lateral (Ai) and intracellular views (Aii) of a representative low energy pose of ﬂecainide (yellow sticks) docked to
an MthK-based open-state hERG channel homology model. Pore region domains are shown as grey ribbons. Green sticks represent residues T623, S624 and V625, whilst Y652
and F656 are shown as pink and blue sticks respectively. K+ ions in the selectivity ﬁlter are shown as purple spheres. (B) Representative low energy GOLD pose for ﬂecainide
(yellow sticks) docked to hERG pore cavity residues. Residues V625, Y652 and F656 are shown as green, pink and blue sticks, respectively. For clarity only three F656 side chains
and three Y652 side chains are shown. The interactions included a π–π interaction (3.7 Å) between the aromatic ring of the benzamide moiety of ﬂecainide and F656, and a
second π–π interaction (3.3 Å) between the piperidine ring and an adjacent F656 (black dotted lines).
Fig. 5. Effect of pore-helix and S6helixmutations on ﬂecainide inhibition of IhERG. (A–C)Upper traces show IhERG elicited by protocols shown as lower traces in control and 10 μM ﬂecainide
for the T623A (A), S624A (B) and V625A (C) pore-helicalmutants. (D–F) Upper traces show IhERG elicited by protocols shown as lower traces in control and 10 μM ﬂecainide for the G648A
(D), Y652A (E) and F656A (F) S6helixmutants. (G) IC50 forﬂecainide inhibition of the alaninemutants shown inA–F, togetherwith those for theirWT IhERG comparators (WT “Standard”—
for S624A and Y652A;WT “inward” for V625A;WT “High K+” for T623A, G648A and F656A). Plotted error bars represent 95% conﬁdence intervals. Each IC50 was derived from a concen-
tration–response relationship derived from at least four different drug concentrations, n ≥ 5 for each concentration on each curve.
51D. Melgari et al. / Journal of Molecular and Cellular Cardiology 86 (2015) 42–53
52 D. Melgari et al. / Journal of Molecular and Cellular Cardiology 86 (2015) 42–53conformations direct interaction with V625 did not occur. Binding of
ﬂecainide relatively low in the pore cavity is further supported by the
lack of effect of altering the direction of K+ ﬂux (i.e. lack of a “knock
off” effect), which suggests that ﬂecainide is unlikely to lie near the
K+ ion conduction pathway. The V625A mutation profoundly attenu-
ates IhERG inactivation [58]. Attenuated inactivation has been proposed
to inﬂuence drug blocking potency by altering the positioning of S6 ar-
omatic binding residues relative to the inner cavity [59], and this may
account for the allosteric effect of V625A on ﬂecainide binding. Support
for such an explanation comes from the marked effect of the N588K/
S631A double mutant, which exhibits little inactivation [33], on
ﬂecainide block, as neither N588 nor S631 lies near the binding site
for ﬂecainide.
4.3. Clinical relevance and implications
As commented in the Introduction text and highlighted by others
[5],ﬂecainide's inhibitory effects on INa and IKr occur at lower concentra-
tions than those on other channels; they are therefore the ion channel
effects that are likely to predominate during clinical use of the drug.
Until recently, the drug's effectiveness against CPVT (e.g. [7–10]) has
been considered to be a direct consequence of inhibition of RyR2
ryanodine receptors (e.g. [7,60]), which in intact cardiomyocytes
would require cell entry of the drug to access RyR2s in the sarcoplasmic
reticulummembrane. However, a very recent study has suggested that
ﬂecainide does not inhibit luminal-to-cytosolic cation ﬂux through
RyR2 and that the drug's beneﬁcial actions in CPVT are secondary to
Na+-dependent modulation of intracellular Ca2+ ion handling [61].
The drug's inhibitory action on Na+ channels may also reduce oxidative
stress at high atrial rates through reducingNa+and, thereby, Ca2+ accu-
mulation [5]. Taken together, prior work on Na+ channels using
ﬂecainide analogues [39] and the results of the present study indicate
that the drug's actions on its principal ion channel targets in the sarco-
lemmal membrane rely on charged drug access to the target channels
from the cell interior.
Although ﬂecainide is recommended as a front-line treatment
option for both pharmacological cardioversion and maintenance of
sinus rhythm in AF patients [2–4], data from the 2005 EuroHeart Survey
on AF suggested that the actual clinical use of the drug is not high (with
~17% and 13% of paroxysmal and persistent AF patients receiving class
Ic drug treatment) [5,62]. However, although the results of the CAST
trial indicate clearly that ﬂecainide should be avoided in patients with
structural heart disease, a review of 25 years of clinical ﬂecainide use
suggests that the drug is a safe and effective treatment option for AF
in younger patients without concomitant structural heart disease [5].
For example, one systematic review of randomized controlled trials
found the incidence of ventricular arrhythmias in AF patients given
ﬂecainide to be 3% or less [63]. Ameta-analysis of 122 studies of patients
receiving ﬂecainide for supraventricular tachycardias, without obvious
signs of ventricular damage, found ﬂecainide to be associated with a
lower incidence of proarrhythmic events than control (2.7 vs. 4.8%)
[64]. Clearly, though, ﬂecainide's ability to inhibit IKr/IhERG at clinically
relevant concentrations makes it important to exercise appropriate
caution in either very carefully monitoring or avoiding the drug's
administration to patients with other risk factors for acquired
LQTS, such as pre-existing QT prolongation, co-administration with
other IKr/IhERG blocking drugs, or hypokalemia.
5. Conclusions
Flecainide acts as a gated state inhibitor of IhERG at clinically relevant
concentrations. Our ﬁndings are consistent with a scheme in which
ﬂecainide crosses the cell membrane and accesses the channel on acti-
vation gating. Our data with QX-Flec and NU-Flec support the notion
of preferential interactions between the charged form of the drug and
a binding sitewithin the hERG inner cavity. Flecainide exhibits a distinctproﬁle of responses to mutations of amino-acid residues that form the
canonical binding site for high afﬁnity inhibitors. It binds low in the
inner cavity and interacts strongly with F656. The effect of inactivation
gating on ﬂecainide block is likely to result from stabilization of drug
binding by optimising drug interactionswith F656 aromatic side chains.
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